KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 119 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $357,039 | -25.0% | 266,447 | +0.1% | 0.00% | – |
| Q2 2023 | $476,303 | -46.8% | 266,091 | +15.7% | 0.00% | – |
| Q1 2023 | $894,598 | +137.2% | 229,974 | +107.3% | 0.00% | – |
| Q4 2022 | $377,131 | -38.4% | 110,921 | -1.0% | 0.00% | – |
| Q3 2022 | $612,000 | +20.7% | 112,094 | -0.4% | 0.00% | – |
| Q2 2022 | $507,000 | -39.6% | 112,517 | -1.3% | 0.00% | – |
| Q1 2022 | $840,000 | – | 113,972 | +5698500.0% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 2 | -100.0% | 0.00% | – |
| Q1 2021 | $833,000 | -66.5% | 79,210 | -50.7% | 0.00% | – |
| Q4 2020 | $2,486,000 | -3.8% | 160,610 | -9.3% | 0.00% | – |
| Q3 2020 | $2,584,000 | -79.8% | 177,010 | -73.8% | 0.00% | -100.0% |
| Q2 2020 | $12,792,000 | -13.4% | 675,410 | -12.2% | 0.00% | -50.0% |
| Q1 2020 | $14,778,000 | +22.0% | 769,298 | +21.8% | 0.00% | +100.0% |
| Q4 2019 | $12,112,000 | +62.6% | 631,798 | -18.4% | 0.00% | 0.0% |
| Q3 2019 | $7,449,000 | +18.7% | 774,300 | -26.1% | 0.00% | 0.0% |
| Q2 2019 | $6,278,000 | -29.9% | 1,048,100 | -31.7% | 0.00% | 0.0% |
| Q1 2019 | $8,957,000 | -49.0% | 1,533,800 | -18.2% | 0.00% | -50.0% |
| Q4 2018 | $17,570,000 | -16.6% | 1,875,140 | +51.5% | 0.00% | 0.0% |
| Q3 2018 | $21,079,000 | -19.4% | 1,237,783 | -19.6% | 0.00% | -33.3% |
| Q2 2018 | $26,168,000 | -35.7% | 1,540,183 | -49.2% | 0.00% | -40.0% |
| Q1 2018 | $40,695,000 | +6.4% | 3,032,392 | -23.9% | 0.01% | +25.0% |
| Q4 2017 | $38,237,000 | -13.1% | 3,983,042 | -0.6% | 0.00% | -20.0% |
| Q3 2017 | $44,006,000 | +12.4% | 4,007,842 | -7.3% | 0.01% | 0.0% |
| Q2 2017 | $39,140,000 | -29.5% | 4,324,831 | 0.0% | 0.01% | -28.6% |
| Q1 2017 | $55,531,000 | +24.9% | 4,324,831 | -8.6% | 0.01% | +16.7% |
| Q4 2016 | $44,463,000 | -14.7% | 4,730,131 | -11.7% | 0.01% | -14.3% |
| Q3 2016 | $52,151,000 | +45.0% | 5,359,831 | 0.0% | 0.01% | +40.0% |
| Q2 2016 | $35,964,000 | -24.8% | 5,359,831 | 0.0% | 0.01% | -28.6% |
| Q1 2016 | $47,810,000 | -32.7% | 5,359,831 | 0.0% | 0.01% | -30.0% |
| Q4 2015 | $71,018,000 | +25.9% | 5,359,831 | +0.1% | 0.01% | +25.0% |
| Q3 2015 | $56,406,000 | -61.3% | 5,356,672 | +0.0% | 0.01% | -57.9% |
| Q2 2015 | $145,688,000 | -8.1% | 5,354,220 | +3.4% | 0.02% | -5.0% |
| Q1 2015 | $158,542,000 | -13.6% | 5,179,416 | +5.6% | 0.02% | -16.7% |
| Q4 2014 | $183,597,000 | +29.5% | 4,905,084 | +20.8% | 0.02% | +26.3% |
| Q3 2014 | $141,823,000 | -10.8% | 4,059,045 | +18.9% | 0.02% | -9.5% |
| Q2 2014 | $158,928,000 | +119.3% | 3,414,131 | +45.5% | 0.02% | +110.0% |
| Q1 2014 | $72,468,000 | +34.8% | 2,346,000 | 0.0% | 0.01% | +25.0% |
| Q4 2013 | $53,770,000 | – | 2,346,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $35,031,000 | 23.03% |
| Palo Alto Investors LP | 5,267,652 | $81,543,000 | 4.28% |
| Fairmount Funds Management LLC | 702,351 | $10,872,000 | 3.89% |
| Birchview Capital, LP | 188,000 | $2,910,000 | 1.68% |
| Mesirow Financial Investment Management, Inc. | 22,303 | $345,250,000 | 1.09% |
| EMERALD ADVISERS, LLC | 1,822,781 | $28,217,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,661,236 | $25,716,000 | 0.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,552,504 | $24,033,000 | 0.85% |
| Altium Capital Management LP | 133,951 | $2,074,000 | 0.77% |
| Hood River Capital Management LLC | 931,754 | $14,424,000 | 0.48% |